Aspira Women's Health Files Q2 10-Q, Details Stock Offerings

Ticker: AWHL · Form: 10-Q · Filed: 2024-08-13T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financing, stock-offering, financials

TL;DR

Aspira Women's Health 10-Q filed: Q2 financials out, stock deals and warrants detailed. Financing continues.

AI Summary

Aspira Women's Health Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, including details on stock offerings and warrant agreements. Key events mentioned include a Purchase Agreement on January 24, 2024, and a subsequent event related to an At-The-Market Offering Agreement with HC Wainwright & Co. on August 2, 2024.

Why It Matters

This filing provides insight into Aspira Women's Health's financial health and strategic financing activities, which can impact investor confidence and future operational capabilities.

Risk Assessment

Risk Level: medium — The company's financial disclosures and ongoing financing activities suggest potential financial pressures or growth-oriented strategies that carry inherent risks.

Key Numbers

20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
2024-01-24 — Purchase Agreement Date (Marks a significant transaction or agreement date.)
2024-08-02 — ATM Offering Agreement Date (Highlights a recent financing or capital-raising event.)

Key Players & Entities

Aspira Women's Health Inc. (company) — Filer of the 10-Q
20240630 (date) — End of reporting period
January 24, 2024 (date) — Date of Purchase Agreement
August 2, 2024 (date) — Date of At-The-Market Offering Agreement
HC Wainwright & Co. (company) — Underwriter for At-The-Market Offering

FAQ

What were the key financial highlights for Aspira Women's Health in the quarter ending June 30, 2024?

The 10-Q filing for the period ending June 30, 2024, details the company's financial performance, though specific revenue or net income figures are not provided in this excerpt.

What is the significance of the Purchase Agreement dated January 24, 2024?

The Purchase Agreement dated January 24, 2024, is noted in relation to common stock and a Chief Executive Officer, suggesting a transaction involving equity or executive compensation.

What subsequent events are highlighted in this filing?

Subsequent events include an amendment to the Milligan Amendment on August 31, 2024, and an At-The-Market Offering Agreement with HC Wainwright & Co. on August 2, 2024.

What types of stock-related agreements are mentioned?

The filing mentions a Purchase Agreement, common stock, warrants (specifically 'TwoThousandAndTwentyTwoWarrantsMember'), and an At-The-Market Offering Agreement.

What was the company's former name?

The company was formerly known as VERMILLION, INC. and CIPHERGEN BIOSYSTEMS INC.

From the Filing

0000950170-24-096220.txt : 20240813 0000950170-24-096220.hdr.sgml : 20240813 20240813161315 ACCESSION NUMBER: 0000950170-24-096220 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240813 DATE AS OF CHANGE: 20240813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241201603 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 10-Q 1 awh-20240630.htm 10-Q 10-Q 0000926617 Q2 False --12-31 2 0000926617 awh:PurchaseAgreementMember srt:ChiefExecutiveOfficerMember 2024-01-24 2024-01-24 0000926617 us-gaap:CommonStockMember awh:PurchaseAgreementMember srt:ChiefExecutiveOfficerMember 2024-01-24 0000926617 us-gaap:CommonStockMember 2023-06-30 0000926617 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000926617 srt:PresidentMember awh:MilliganAmendmentMember us-gaap:SubsequentEventMember 2024-08-31 2024-08-31 0000926617 awh:TwoThousandAndTwentyTwoWarrantsMember 2023-12-31 0000926617 awh:LPCPurchaseAgreementMember 2023-01-01 2023-06-30 0000926617 awh:StockOffering2022Member 2023-01-01 2023-12-31 0000926617 awh:AtTheMarketOfferingAgreementMember awh:HCWainwrightCoMember us-gaap:SubsequentEventMember 2024-08-02 0000926617 awh:MinimumSharePurchaseStockPriceRangeTwoMember awh:LPCPurchaseAgreementMember 2023-03-28 2023-03-28 0000926617 awh:DecdLoanMember 2016-03-22 2016-03-22 0000926617 awh:MinimumSharePurchaseStockPriceRangeTwoMember awh:LPCPurchaseAgreementMember 2023-03-28 0000926617 awh:LPCPurchaseAgreementMember 2023-03-28 2023-03-28 0000926617 us-gaap:CommonStockMember awh:EquityLineOfCreditAgreementMember 2024-01-01 2024-03-31 0000926617 us-gaap:ProductMember 2023-01-01 2023-06-30 0000926617 awh:DirectorsAndExecutiveOfficersMember awh:PurchaseAgreementMember 2023-07-20 2023-07-20 0000926617 awh:LincolnParkCapitalFundMember us-gaap:SubsequentEventMember srt:MaximumMember awh:PurchaseAgreementMember 2024-08-09 0000926617 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000926617 awh:AugustTwoThousandTwentyTwoWarrantsMember awh:WarrantInducementAgreementMember us-gaap:SubsequentEventMember 2024-07-31 0000926617 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000926617 awh:DirectorsAndExecutiveOfficersMember awh:PurchaseAgreementMember 2023-07-20 0000926617 us-gaap:CostOfSalesMember 2024-04-01 2024-06-30 0000926617 us-gaap:ProductMember 2024-04-01 2024-06-30 0000926617 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000926617 awh:LPCPurchaseAgreementMember 2023-03-28 2024-06-30 0000926617 awh:SponsoredResearchAgreementMember 2023-01-01 2023-06-30 0000926617 awh:ConsultingAgreementMember us-gaap:SubsequentEventMember awh:InterimChiefFinancialOfficerMember 2024-08-12 2024-08-12 0000926617 awh:InsuranceNotesMember 2023-01-01 2023-06-30 0000926617 awh:EquityLineOfCreditAgreementMember 2023-04-01 2023-06-30 0000926617 us-gaap:RestrictedStockMember 2024-06-30 0000926617 awh:InsuranceNotesMember 2024-04-01 2024-06-30 0000926617 2023-01-01 2023-06-30 0000926617 awh:CompletionOfCertainDeliverablesFirstMember awh:SponsoredResearchAgreementMember 2023-01-01 2023-12-31 0000926617 awh:EquityLineOfCreditAgreementMember 2024-01-01 2024-03-31 0000926617 awh:RegisteredDirectOfferingMember 2024-01-0